- Entry
- $4.53
- Final
- $3.75 -17.2%
- Target
- $30.00
- Score
- -0.03
Been buying this beauty since it was $1.25 and intend to hold until the fall. By then, analysts expect it to be $25-30/share. This is a Paul Schimmel (Billionaire Biotech Chemist) company and they’ve got a miracle drug to treat lung inflammation, which hasn’t seen anything new in 60 years. But instead of using steroids, which have horrible long-term side effects, ATYR’s drug heals with none. This is a $5B opportunity and ATYR has no competition. Closest competitor is 5 …
— ORIGINAL POST ·
ATYR Won’t Be a “Penny Stock” for Long
· r/wallstreetbets
· Feb 20, 2025